Issue: July 2019
Perspective from Sanjiv J. Shah, MD
May 06, 2019
1 min read

Treatments for cardiomyopathy from transthyretin-mediated amyloidosis approved by FDA

Issue: July 2019
Perspective from Sanjiv J. Shah, MD
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The FDA approved two treatments for patients with cardiomyopathy associated with transthyretin-mediated amyloidosis.

Tafamidis meglumine (Vyndaqel, FoldRx/Pfizer) and tafamidis (Vyndamax, FoldRx/Pfizer) are the first treatments for transthyretin-mediated amyloidosis that were approved by the FDA, according to a press release from the agency. Recommended doses for each treatment differ and are not substitutable on a milligram-to-milligram basis despite having the same active moiety.

The recommended dose is 80 mg once per day of tafamidis meglumine, which is given as four 20-mg capsules, and 61 mg of tafamidis once per day, which is given as a single capsule. The single-capsule formulation was developed by Pfizer for patient convenience, according to a press release from the company.

“Transthyretin-mediated amyloidosis is a rare, debilitating and often fatal disease,” Norman Stockbridge, MD, PhD, director of the division of cardiovascular and renal drugs at the Center for Drug Evaluation and Research of the FDA, said in the release. “The treatments we’re approving today are an important advancement in the treatment of the cardiomyopathy caused by transthyretin-mediated amyloidosis.”

Both formulations selectively bind to transthyretin to stabilize the tetramer of the transthyretin transport protein and reduce amyloid formation, according to the release.

The approval of both treatments was based on results from the ATTR-ACT trial. As Cardiology Today previously reported, treatment with tafamidis reduced risk for all-cause mortality and CV-related hospitalizations in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy.

Tafamidis meglumine was previously granted priority review, fast track and breakthrough therapy designations by the FDA, according to the release. Both treatments were given orphan drug designation by the FDA.

Disclosures: The ATTR-ACT trial was funded by Pfizer. Stockbridge is an employee of the FDA.